Cisplatin in-vitro activity with co-exposure to MRI

In the present work, we investigate the influence of concomitant exposure to a clinical magnetic resonance imaging (MRI) electromagnetic environment together with cisplatin (CDDP) on the in-vitro chemosensitivity of cell lines from the ovarian cancer panel (SW626, PA-1, Caov3, SK-OV-3). CDDP treatment concentration was close to half of the maximal inhibitory concentration (IC50). We used a MRI-compatible incubation set-up for applying electromagnetic exposures consisting in three different imaging sequences generated by a 3-T clinical instrument: a T2-weighted 2D turbo-spin echo (TSE), a 3D TSE, and, a gradient-recalled echo (GRE). We assessed cell viability at 68-h after the joint chemical and electromagnetic treatment. Overall, our results do not show significant impact of simultaneous MRI and CDDP exposure on the in-vitro activity in various ovarian cancer cell lines, suggesting that it is pharmacologically safe. Overall, the implemented set-up revealed high performances.